Determination of Tofacitinib in Mice Whole Blood on Dried Blood Spots Using LC–ESI–MS/MS: Application to Pharmacokinetic Study in Mice

Abstract

A simple, sensitive and rapid assay method has been developed and validated as per regulatory guideline for the estimation of tofacitinib on mice dried blood spots (DBS) using liquid chromatography coupled to tandem mass spectrometry with electro spray ionization in the positive-ion mode. The method employs liquid extraction of tofacitinib from DBS disk of mice whole blood followed by chromatographic separation using 5 mM ammonium acetate (pH 6.5):acetonitrile (20:80, v/v) at a flow rate of 0.60 mL/min on an X-Terra Phenyl column with a total run time 2.5 min. The MS/MS ion transitions monitored were m/z 313→149 for tofacitinib and m/z 316→149 for the internal standard (¹³C_3, ¹⁵N-tofacitinib). The assay was linear in the range of 0.99–1980 ng/mL. The intra- and inter-day precision was in the range of 1.17–10.3 and 3.37–10.9%, respectively. Stability studies showed that tofacitinib was stable on DBS cards for one month. This novel method has been applied to analyze the DBS samples of tofacitinib obtained from a pharmacokinetic study in mice.

Key words

Tofacitinib - dried blood spot - LC-MS/MS - method validation - mice - pharmacokinetics

• References

• 1 Ivashkiv LB, Hu X. The JAK/STAT pathway in rheumatoid arthritis: Pathogenic or protective?. Arthritis Rheum 2003; 48: 2092-2096
• 2 Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 2005; 32: 1650-1653
• 3 Meyer DM, Jesson MI, Li X. et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm 2010; 7: 41
• 4 Milici AJ, Kudlacz EM, Audoly L. et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008; 10: R14
• 5 LaBranche TP, Jesson MI, Radi ZA. et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 2012; 64: 3531-3542
• 6 Ghoreschi K, Jesson MI, Li X. et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186: 4234-4243
• 7 Lee EB, Fleischmann R, Hall S. et al. Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-naive patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: S1049
• 8 van Vollenhoven RF, Fleischmann R, Cohen S. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-519
• 9 Fleischmann R, Kremer J, Cush J. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507
• 10 Kremer J, Li ZG, Hall S. et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. Ann Intern Med 2013; 159: 253-261
• 11 Burmester GR, Blanco R, Charles-Schoeman C. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet 2013; 381: 451-460
• 12 van der Heijde D, Tanaka Y, Fleischmann R. et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-570
• 13 Paniagua R, Campbell A, Changelian PS. et al. Quantitative analysis of the immunosuppressant CP-690,550 in whole blood by column-switching high-performance liquid chromatography and mass spectrometry detection. Ther Drug Monit 2005; 27: 608-616
• 14 Dowty ME, Lin J, Ryder TF. et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos 2014; 42: 759-773
• 15 Sharma K, Giri K, Dhiman V. et al. A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: Application to a pharmacokinetic study. Biomed Chromatogr 2015; 29: 722-732
• 16 Kadi AA, Abdelhameed AS, Darwish HW. et al. Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine. Trop J Pharm Res 2016; 15: 2683-2692
• 17 Abdelhameed AS, Attwa MW, Kadi AA. An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma. Biomed Chromatogr 2017; 31: e3793
• 18 US DHHS, FDA, CDER, CVM, Guidance for Industry: Bioanalytical method validation. U.S. department of health and human services, food and drug administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). 2018. Rockville, MD, USA.:
• 19 Freeman JD, Rosman LM, Ratcliff JD. et al. State of the science in dried blood spots. Clin Chem 2018; 64: 656-679
• 20 Demirev PA. Dried blood spots: analysis and applications. Anal Chem 2013; 85: 779-789